OncoMatch/Clinical Trials/NCT01898039
Modified Vaccine for High Risk or Low Residual Melanoma Patients
Is NCT01898039 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including A2/4-1BBL melanoma vaccine and Cyclophosphamide for malignant melanoma.
Treatment: A2/4-1BBL melanoma vaccine · Cyclophosphamide — This study is designed for patients who had malignant melanoma and, following tumor removal, are now free of disease, or have only very minor residual disease, and are at a very high risk of disease recurrence. These patients will be treated with the A2/4-1BBL melanoma vaccine, a compatible melanoma cell line that has been engineered to express a molecule termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's immune system, and to induce its stimulation. The hypothesis that drives the study states that the immune response against the cell line will also be effective against the residual tumor that may still be present in the body.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Biomarker criteria
Allowed: BRAF v600e
Allowed: BRAF wild-type
Disease stage
Required: Stage IIB, IIC, III, IV
Prior therapy
Must have received: chemotherapy (DTIC, temodal, taxanes, platinum compounds)
at least two treatment lines, including chemotherapy (DTIC, temodal, taxanes, platinum compounds)
Must have received: anti-CTLA-4 therapy (ipilimumab)
anti-CTLA-4 (ipilimumab)
Must have received: BRAF inhibitor
B-RAF inhibitor if harboring the V600E BRAF mutation in their tumor
Cannot have received: cytotoxic drugs
Exception: if administered less than 28 days prior to protocol administration
Administration of cytotoxic drugs or extensive radiotherapy less than 28 days prior to protocol administration
Cannot have received: extensive radiotherapy
Exception: if administered less than 28 days prior to protocol administration
Administration of cytotoxic drugs or extensive radiotherapy less than 28 days prior to protocol administration
Lab requirements
Blood counts
hematocrit >25% and wbc >3000
Cardiac function
no active cardio-respiratory disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify